Prof. Guy Jerusalem presents a clinical case of estrogen receptor (ER) positive human epidermal growth factor receptor 2 negative advanced breast cancer. He discusses how advanced breast cancer patients with unfavorable prognostic factors appear to receive the maximum benefits from abemaciclib plus endocrine therapy.1,2 Reference 1. Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. Journal of Clinical Oncology.
2017 Nov 10;35(32):3638-46. 2. Di Leo A, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tredan O, Chen SC, Manso L, Freedman O. MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2-advanced breast cancer. Annals of Oncology. 2017 Sep 1;28:v609.
